Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST and Pharmacokinetic/Pharmacodynamic) in Prognosis of Bacteremia by Enterobacteriaceae

NCT02005159 is registered in ClinicalTrials.gov with Fundación Pública Andaluza Progreso y Salud as lead sponsor.

NCT NCT02005159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02005159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST and Pharmacokinetic/Pharmacodynamic) in Prognosis of Bacteremia by Enterobacteriaceae
Lead sponsor
Fundación Pública Andaluza Progreso y Salud
Phase
Observational
Overall status
Completed
Start date
March 31, 2011
Completion date
December 31, 2014
Enrollment
1,064 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

bacteremia by enterobacteriaceae